Phase 3 Alzheimer's Disease Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• A person must have a diagnosis of Alzheimer's disease based on a specific set of medical criteria known as IWG-2.
• The person must be 50 years of age or older.
• The person must not be under any form of legal protection, such as guardianship or curatorship.
• The person must have a score of 10 or higher on a memory and thinking test called the MMSE.
• The person must have abnormal levels of a protein called Aβ42, or an abnormal ratio of Aβ40 to Aβ42, measured from spinal fluid.
• The person must have abnormal levels of a protein called phosphorylated Tau, also measured from spinal fluid.
• If the person scores below 20 on the MMSE, a family carer or someone living with them must be available to help make sure the treatment is taken correctly.
• The person must be a native French speaker.

Who may not be able to join:

• People whose memory or thinking problems are caused by something other than Alzheimer's disease.
• People who have previously used any medication specifically prescribed to treat the symptoms of Alzheimer's disease.
• People with a known allergy or sensitivity to donepezil hydrochloride or any of its listed ingredients.
• People with certain heart conditions, such as an unusually slow heart rate, problems with the heart's electrical signalling, or certain types of heart conduction disorders (confirm with trial site).
• People taking any medications known to affect a specific heart rhythm measurement called the QTc interval.
• People who are at high risk of stomach ulcers, have a known history of ulcers, or are taking anti-inflammatory pain medicines (such as ibuprofen-type drugs).
• People who are at risk of difficulty passing urine (urinary retention).
• People with a history of epilepsy or seizures.
• People with a history of a serious reaction to antipsychotic medications called neuroleptic malignant syndrome.
• People with a history of asthma or chronic obstructive lung disease.
• People with severely reduced liver function.
• People currently taking certain medications that can interact with the trial treatment, including some antifungals, some antibiotics, some heart rhythm medications, some antipsychotic medications, and some anti-seizure medications (confirm full list with trial site).
• People who are already taking part in another clinical trial that involves an intervention.

Important: Always verify eligibility with the trial site directly before applying.